BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26636678)

  • 21. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
    Mazzio EA; Soliman KF
    Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.
    Mercado GE; Xia SJ; Zhang C; Ahn EH; Gustafson DM; Laé M; Ladanyi M; Barr FG
    Genes Chromosomes Cancer; 2008 Jun; 47(6):510-20. PubMed ID: 18335505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
    Richon VM; Sandhoff TW; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells.
    Beccafico S; Morozzi G; Marchetti MC; Riccardi C; Sidoni A; Donato R; Sorci G
    Carcinogenesis; 2015 Sep; 36(9):1071-83. PubMed ID: 26153023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plakoglobin is differentially expressed in alveolar and embryonal rhabdomyosarcoma and is regulated by DNA methylation and histone acetylation.
    Gastaldi T; Bonvini P; Sartori F; Marrone A; Iolascon A; Rosolen A
    Carcinogenesis; 2006 Sep; 27(9):1758-67. PubMed ID: 16537559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
    Li G; Xie Q; Yang Z; Wang L; Zhang X; Zuo B; Zhang S; Yang A; Jia L
    Int J Cancer; 2019 Dec; 145(12):3285-3298. PubMed ID: 31111958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
    He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T
    Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
    Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.
    Slemmons KK; Crose LES; Riedel S; Sushnitha M; Belyea B; Linardic CM
    Mol Cancer Res; 2017 Dec; 15(12):1777-1791. PubMed ID: 28923841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.
    Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K
    Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness.
    Chiappalupi S; Riuzzi F; Fulle S; Donato R; Sorci G
    Carcinogenesis; 2014 Oct; 35(10):2382-92. PubMed ID: 25123133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of RAS on the genesis of embryonal rhabdomyosarcoma.
    Langenau DM; Keefe MD; Storer NY; Guyon JR; Kutok JL; Le X; Goessling W; Neuberg DS; Kunkel LM; Zon LI
    Genes Dev; 2007 Jun; 21(11):1382-95. PubMed ID: 17510286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
    Pal A; Leung JY; Ang GCK; Rao VK; Pignata L; Lim HJ; Hebrard M; Chang KT; Lee VK; Guccione E; Taneja R
    Elife; 2020 Nov; 9():. PubMed ID: 33252038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
    Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
    Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.